April 28, 2020 / 9:48 PM / a month ago

BRIEF-Bergenbio's Bemcentinib Selected To Be Fast-Tracked As Potential Treatment For COVID-19

April 28 (Reuters) - Bergenbio ASA:

* BERGENBIO’S BEMCENTINIB SELECTED TO BE FAST-TRACKED AS POTENTIAL TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT CLINICAL TRIAL INITIATIVE

* BERGENBIO ASA - BEMCENTINIB SELECTED AS FIRST CANDIDATE TO BE TESTED THROUGH NEW ACCORD STUDY

* BERGENBIO ASA - PHASE II CLINICAL TRIAL INITIATIVE TO RAPIDLY INVESTIGATE BEMCENTINIB’S EFFICACY AND SAFETY IN HOSPITALISED COVID-19 PATIENTS

* BERGENBIO ASA - STUDY TO BE FUNDED BY UK DEPARTMENT OF HEALTH AND SOCIAL CARE AND UK RESEARCH AND INNOVATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below